These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 16518709

  • 1. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H, Dalhoff A.
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I, Cars O.
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [Abstract] [Full Text] [Related]

  • 3. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM, Reese AA, Ostroski M, Hoban DJ, Zhanel GG.
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [Abstract] [Full Text] [Related]

  • 4. Determination of moxifloxacin anaerobic susceptibility breakpoints according to the Clinical and Laboratory Standards Institute guidelines.
    Ambler J, Rennie R, Poupard J, Koeth L, Stass H, Endermann R, Choudhri S.
    Diagn Microbiol Infect Dis; 2008 May; 61(1):49-57. PubMed ID: 18342475
    [Abstract] [Full Text] [Related]

  • 5. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA, Du X, Nicolau DP.
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [Abstract] [Full Text] [Related]

  • 7. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP).
    Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG.
    Int J Antimicrob Agents; 2004 Nov; 24(5):479-84. PubMed ID: 15519481
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG, Schaeftlein A, Haeberle HA, Kees F, Kloft C, Heininger A.
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B.
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [Abstract] [Full Text] [Related]

  • 12. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
    Firsov AA, Vostrov SN, Lubenko IY, Portnoy YA, Zinner SH.
    Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
    [Abstract] [Full Text] [Related]

  • 13. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
    Alou L, Giménez MJ, Sevillano D, Aguilar L, Cafini F, Echeverría O, Pérez-Trallero E, Prieto J.
    J Antimicrob Chemother; 2006 Aug; 58(2):349-58. PubMed ID: 16782744
    [Abstract] [Full Text] [Related]

  • 14. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D, Zhong M, Mattoes H, Bui KQ, McNabb J, Nicolau DP, Quintiliani R, Nightingale CH.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.
    Kontou P, Manika K, Chatzika K, Papaioannou M, Sionidou M, Pitsiou G, Kioumis I.
    Int J Antimicrob Agents; 2013 Sep; 42(3):262-7. PubMed ID: 23830621
    [Abstract] [Full Text] [Related]

  • 16. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA, Ariano RE, Iacovides H, Sun S, Harding GK.
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [Abstract] [Full Text] [Related]

  • 17. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci.
    Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Bhavnani SM, Ellis-Grosse E.
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):155-9. PubMed ID: 19150707
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.